These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Dose escalation in brachytherapy for cervical cancer: impact on (or increased need for) MRI-guided plan optimisation.
    Author: Paton AM, Chalmers KE, Coomber H, Cameron AL.
    Journal: Br J Radiol; 2012 Dec; 85(1020):e1249-55. PubMed ID: 23175490.
    Abstract:
    OBJECTIVE: The aim of this study was to assess the impact of dose escalation on the proportion of patients requiring MR image-guided optimisation rather than standard Manchester-based CT-guided planning, and the level of escalation achievable. METHODS: 30 patients with cervical cancer treated with external beam radiotherapy and image-guided brachytherapy (IGBT) had MR images acquired at the first fraction of IGBT. Gross tumour volume and high-risk clinical target volume (HR CTV) were contoured and treatment plans retrospectively produced for a range of total 2-Gy equivalent (EQD2) prescription doses from 66 Gy(α/β=10) to 90 Gy(α/β=10) (HR CTV D90). Standard Manchester system-style plans were produced, prescribed to point A and then optimised where necessary with the aim of delivering at least the prescription dose to the HR CTV D90 while respecting organ-at-risk (OAR) tolerances. RESULTS: Increasing the total EQD2 from 66 Gy(α/β=10) to 90 Gy(α/β=10) increased the number of plans requiring optimisation from 13.3% to 90%. After optimisation, the number of plans achieving the prescription dose ranged from 93.3% (66 Gy(α/β=10)) to 63.3% (90 Gy(α/β=10)) with the mean ± standard deviation for HR CTV D90 EQD2 from 78.4 ± 12.4 Gy(α/β=10) (66 Gy(α/β=10)) to 94.1 ± 19.9 Gy(α/β=10) (90 Gy(α/β=10)). CONCLUSION: As doses are escalated, the need for non-standard optimised planning increases, while benefits in terms of increased target doses actually achieved diminish. The maximum achievable target dose is ultimately limited by proximity of OARs. ADVANCES IN KNOWLEDGE: This work represents a guide for other centres in determining the highest practicable prescription doses while considering patient throughput and maintaining acceptable OAR doses.
    [Abstract] [Full Text] [Related] [New Search]